Thursday, August 17, 2017 10:44:19 PM
I see some that think that HDC wins both lawsuits that they think that is the answer but it is not. What kills HDC is simple! NO PRODUCTS of our own. Mark Moore has plenty of knowledge to make a go of things so why is that not happening? (We have NOTHING for anyone to buy) and as you know each CEO that comes in knows absolutely ZERO about the technologies but they here SVM has so much potential. Now look at potential in a different way...you may have seen kids in school many years ago that had so much potential or did it just look that way? Potential seems to be the SOS everyday & never ever changing for any real positive results.
Even if both the patent & Neogenomic's resolve in our favor any income will directly be taken - bought sold by those holding those "C" shares plus management will dig into those funds and finally pay themselves but hopefully not do a "Barnhill shuffle" on us.
We must have a real product worth buying and not just parts of technology that just enhances. We enhance the "Manifold" company with SVM Capital then after they screwed around long enough Manifold enhanced the SVM technology enough to make it sound like our technology wasn't as worthy??? Was that BS talk and Mark Moore not standing up or as I believe a deal between them that left HDVY out in the cold. I the past we have seen people use our technology as long as 10 years and no results. WTF!!!
BTW- It is mandatory that HDC protect and maintain maintenance of any patent involved within the contract dealings with NeoGenomics. If not that can be taken as a breach of contract. Is it possible the reason why they are fighting Intel!!!
Recent HDVY News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 09:13:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 07:53:39 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM